<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01057758</url>
  </required_header>
  <id_info>
    <org_study_id>2008-002019-42</org_study_id>
    <secondary_id>2008 13</secondary_id>
    <nct_id>NCT01057758</nct_id>
  </id_info>
  <brief_title>STATIN-VAP STATIN-VAP - STATINs and Ventilator-Associated Pneumonia</brief_title>
  <official_title>Effect of the Association of a Statin to Antibiotics on the Prognosis of Patients Presenting With a Suspicion of Ventilator-associated Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective is to assess the efficacy and safety of oral simvastatin in patients with a&#xD;
      suspicion of ventilator-associated pneumonia (VAP). The hypothesis of this study is that&#xD;
      simvastatin therapy will improve mortality in patients a suspicion of VAP.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      When a patient will present a suspicion of VAP (Clinical Pulmonary Infection Score modified ≥&#xD;
      5), Simvastatin or placebo will be administered with antibiotics. Quantitative cultures will&#xD;
      be performed for microbiological confirmation of VAP. Simvastatin or placebo will be&#xD;
      administered through an enteral feeding tube or administered orally when patients are able to&#xD;
      safely take oral medications. The type and placement of the enteral feeding tube&#xD;
      (nasogastric, nasoenteric, PEG, orogastric, oroenteric, etc.) and the ability to safely take&#xD;
      oral medications will be determined by the patient's primary team. Study drug will be blinded&#xD;
      with an identical appearing placebo.&#xD;
&#xD;
      Sequential Organ Failure Assessment score (SOFA), and various blood factors will be measured&#xD;
      during treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    stopped for futility&#xD;
  </why_stopped>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Primary efficacy measure is hospital mortality to day 28.</measure>
    <time_frame>28 days after randomization</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">300</enrollment>
  <condition>Pneumonia</condition>
  <arm_group>
    <arm_group_label>PLACEBO</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Half of the patients will be randomized to the placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Simvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Half of the subjects will receive the active drug, Simvastatin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SIMVASTATIN</intervention_name>
    <description>Patients will receive 60 mg of study drug daily by mouth or feeding tube for 28 days or until discharged from the study ICU.</description>
    <arm_group_label>Simvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PLACEBO</intervention_name>
    <description>Patients will receive one placebo by mouth or feeding tube daily for 28 days or until discharged form study ICU</description>
    <arm_group_label>PLACEBO</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Duration of mechanical ventilation &gt; 48 h&#xD;
&#xD;
          -  First episode of suspicion of VAP with a Clinical Pulmonary Infection Score modified ≥&#xD;
             5&#xD;
&#xD;
          -  BAL, plugged telescopic catheter and/or tracheal aspirates quantitative cultures&#xD;
             performed prior administration of antibiotics&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Statin treatment received under mechanical ventilation&#xD;
&#xD;
          -  Age less than 18 years&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Unable to receive or unlikely to absorb enteral study drug&#xD;
&#xD;
          -  Patient, surrogate, or physician not committed to full support ).&#xD;
&#xD;
          -  Moribund patient with a SAPS II score &gt; 75&#xD;
&#xD;
          -  Simvastatin specific exclusions Allergy or intolerance to statins Physician insistence&#xD;
             for the use or avoidance of statins during the current hospitalization CK , ALT or AST&#xD;
             &gt; 5 times the upper limit of normal Receiving cyclosporine, gemfibrozil, lopinavir,&#xD;
             ritonavir itraconazole, kétoconazole, érythromycine, clarithromycine, télithromycine,&#xD;
             néfazodone, verapamil, diltiazem&#xD;
&#xD;
          -  Severe chronic liver disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>LAURENT PAPAZIAN</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique Hopitaux De Marseille</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Assistance Publique Hopitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>January 26, 2010</study_first_submitted>
  <study_first_submitted_qc>January 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2010</study_first_posted>
  <last_update_submitted>October 29, 2013</last_update_submitted>
  <last_update_submitted_qc>October 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Suspicion of ventilator-associated pneumonia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Pneumonia, Ventilator-Associated</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

